Athira Pharma (NASDAQ:LONA) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Athira Pharma (NASDAQ:LONA) from a sell rating to a hold rating in a research report released on Saturday morning.

Several other research analysts also recently commented on LONA. Mizuho upgraded Athira Pharma from a “neutral” rating to an “outperform” rating and set a $10.00 price objective on the stock in a report on Thursday, February 19th. Cantor Fitzgerald assumed coverage on Athira Pharma in a report on Thursday, February 26th. They issued an “overweight” rating on the stock. Zacks Research raised Athira Pharma to a “hold” rating in a research note on Friday, February 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research note on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.00.

Athira Pharma Stock Performance

LONA opened at $11.26 on Friday. The stock has a market capitalization of $105.73 million, a P/E ratio of -2.16 and a beta of 1.98. The business has a 50-day moving average of $9.22. Athira Pharma has a 12 month low of $2.51 and a 12 month high of $14.21.

Athira Pharma (NASDAQ:LONA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.73) EPS for the quarter. Analysts expect that Athira Pharma will post -3.75 earnings per share for the current year.

Insider Activity

In related news, CEO Mark James Litton sold 5,156 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $5.37, for a total value of $27,687.72. Following the sale, the chief executive officer directly owned 57,926 shares of the company’s stock, valued at $311,062.62. This trade represents a 8.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 9,110 shares of company stock valued at $48,921 over the last quarter. 25.07% of the stock is owned by company insiders.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.